13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
56 檔
30.6%
In Q1 2024, Octagon Capital Advisors LP's U.S. equity holdings reached a combined market value of $1.1B, distributed across 56 disclosed stock positions.
During Q1 2024, Octagon Capital Advisors LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 21.18% | — | +7.13% | |
| 2 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 5.90% | — | — | |
| 3 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.96% | -1.94% | +149.22% | |
| 4 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.57% | — | — | |
| 5 | DYN | Dyne Therapeutics Inc | Stock-Other | 4.23% | — | +56.75% | |
| 6 | AVBP | Arrivent Biopharma Inc | Stock-Other | 4.16% | +1.12% | — | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 3.71% | — | -11.21% | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.79% | -3.30% | EXIT | |
| 9 | EYPT | Eyepoint Inc | Stock-Other | 2.71% | — | — | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.64% | -1.14% | — | |
| 11 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.60% | — | +22.37% | |
| 12 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.56% | — | -2.38% | |
| 13 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.43% | — | — | |
| 14 | ISREUR | Isoray Inc | Stock-Other | 2.10% | — | — | |
| 15 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.90% | — | — | |
| 16 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.90% | — | — | |
| 17 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 1.79% | — | — | |
| 18 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.76% | — | — | |
| 19 | ANNX | Annexon Inc | Stock-Other | 1.76% | — | — | |
| 20 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.63% | — | +67.24% | |
| 21 | ✓ | Stock-Other | 1.43% | — | — | ||
| 22 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.30% | — | — | |
| 23 | GOSS | Gossamer Bio Inc | Stock-Other | 1.30% | -0.17% | — | |
| 24 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.16% | — | — | |
| 25 | GLYCEUR | Glycomimetics Inc | Stock-Other | 1.08% | — | — | |
| 26 | IMVT | Immunovant Inc | Stock-Other | 1.06% | — | — | |
| 27 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.04% | +1.55% | — | |
| 28 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.03% | — | — | |
| 29 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.99% | — | — | |
| 30 | CYBNEUR | Cybin Inc | Stock-Other | 0.92% | — | — | |
| 31 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.86% | — | — | |
| 32 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.85% | — | — | |
| 33 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.82% | — | — | |
| 34 | PEPG | Pepgen Inc | Stock-Other | 0.66% | — | — | |
| 35 | ✓ | Vincerx Pharma Inc | Stock-Other | 0.61% | — | — | |
| 36 | NUVB | Nuvation Bio Inc | Stock-Other | 0.60% | — | +37.49% | |
| 37 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 0.58% | — | +810.00% | |
| 38 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.54% | — | — | |
| 39 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.49% | -3.09% | EXIT | |
| 40 | FATE | Fate Therapeutics Inc | Stock-Other | 0.46% | — | — | |
| 41 | ✓ | Reneo Pharmaceuticals Inc | Stock-Other | 0.45% | — | — | |
| 42 | ANAB | Anaptysbio Inc | Stock-Other | 0.45% | — | +37.50% | |
| 43 | SANA | Sana Biotechnology Inc | Stock-Other | 0.43% | — | — | |
| 44 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.43% | — | +65.97% | |
| 45 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.39% | — | — | |
| 46 | ✓ | Stock-Other | 0.38% | — | — | ||
| 47 | VERUEUR | Veru Inc | Stock-Other | 0.32% | — | — | |
| 48 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.31% | — | — | |
| 49 | NKTX | Nkarta Inc | Stock-Other | 0.31% | — | — | |
| 50 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.31% | — | — |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 56 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, NVLSEUR, DNTH) accounted for 30.6% of total reported equity market value during Q1 2024.
During Q1 2024, Octagon Capital Advisors LP's top holdings by market value included APLSUSD (21.2%)、NVLSEUR (5.9%)、DNTH (5.0%). The largest single position, APLSUSD, represented 21.2% of total portfolio value.
In Q1 2024, Octagon Capital Advisors LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.